BDP1 and ovarian serous adenocarcinoma: Analysis using GEPIA identifies TP53 as significantly overexpressed in serous ovarian cancer, p = 0.01, Figure 2E and the individual patient data used for analysis of disease‐free progression in patients with BDP1 mutations (Figure 1C) shows that 62% of patients recorded with disease‐free events had a mutation in TP53 (data not shown).